An independent fairness opinion can help board members, special board committees, limited partner advisory committees and others fulfill their fiduciary duties by providing them with a comprehensive analysis and unbiased opinion of the financial aspects of a transaction, such as de-SPAC transactions, acquisitions, divestitures, other M&A transactions, related party transactions, GP-led secondary transactions (and other transactions between funds which are under common management), down-round financings, equity repurchase transactions, recapitalizations, buy-side acquisition transactions with a target in early development, and other material transactions. Our team at RNA Advisors exhibits a depth of life science and healthcare industry knowledge and capital markets, the ability to rapidly identify opportunities and challenges that help our clients make key strategic decisions, and a familiarity with life sciences transaction structures and industry players enabling us to close deals more successfully. Our clients understand that the true value of a fairness opinion is tied to the credentials and experience of the firm rendering it as they may need to defend analyses under the scrutiny of detailed cross-examination.
